Yi-Bo Gao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2634811/publications.pdf

Version: 2024-02-01

257101 161609 3,236 72 24 54 citations h-index g-index papers 77 77 77 5244 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Genetic landscape of esophageal squamous cell carcinoma. Nature Genetics, 2014, 46, 1097-1102.	9.4	600
2	LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut, 2014, 63, 1700-1710.	6.1	385
3	Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. Journal of Thoracic Oncology, 2020, 15, 816-826.	0.5	272
4	Exosomes: New players in cancer. Oncology Reports, 2017, 38, 665-675.	1.2	122
5	MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochemical and Biophysical Research Communications, 2012, 421, 640-645.	1.0	115
6	Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncology, The, 2021, 22, 1265-1274.	5.1	102
7	MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. Medical Oncology, 2013, 30, 411.	1.2	93
8	Folate Receptor-Positive Circulating Tumor Cells as a Novel Diagnostic Biomarker in Non-Small Cell Lung Cancer. Translational Oncology, 2013, 6, 697-702.	1.7	93
9	Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients. Tumor Biology, 2016, 37, 9323-9331.	0.8	81
10	Development and validation of an immuneâ€related prognostic signature in lung adenocarcinoma. Cancer Medicine, 2020, 9, 5960-5975.	1.3	79
11	WNT/ \hat{l}^2 -catenin-suppressed FTO expression increases m6A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis. Cell Death and Disease, 2021, 12, 462.	2.7	75
12	METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding. Nature Communications, 2021, 12, 3803.	5.8	74
13	Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. Oncotarget, 2018, 9, 13920-13933.	0.8	60
14	Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review. Chinese Journal of Cancer, 2017, 36, 65.	4.9	55
15	High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation. Journal of Experimental and Clinical Cancer Research, 2017, 36, 84.	3.5	54
16	Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma. Journal of Cancer, 2019, 10, 3188-3196.	1.2	54
17	Identification of Isocitrate Dehydrogenase 1 as a Potential Diagnostic and Prognostic Biomarker for Non-small Cell Lung Cancer by Proteomic Analysis. Molecular and Cellular Proteomics, 2012, 11, M111.008821.	2.5	52
18	Apolipoprotein E Overexpression Is Associated With Tumor Progression and Poor Survival in Colorectal Cancer. Frontiers in Genetics, 2018, 9, 650.	1.1	45

#	Article	IF	Citations
19	GADD45B as a Prognostic and Predictive Biomarker in Stage II Colorectal Cancer. Genes, 2018, 9, 361.	1.0	45
20	TGF-β-induced NKILA inhibits ESCC cell migration and invasion through NF-κB/MMP14 signaling. Journal of Molecular Medicine, 2018, 96, 301-313.	1.7	44
21	MiRNA expression profile reveals a prognostic signature for esophageal squamous cell carcinoma. Cancer Letters, 2014, 350, 34-42.	3.2	43
22	Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. Cancer Letters, 2018, 423, 9-15.	3.2	38
23	Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Non–Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 5136-5145.	3.2	37
24	AJUBA promotes the migration and invasion of esophageal squamous cell carcinoma cells through upregulation of MMP10 and MMP13 expression. Oncotarget, 2016, 7, 36407-36418.	0.8	35
25	Comprehensive Analysis Uncovers Prognostic and Immunogenic Characteristics of Cellular Senescence for Lung Adenocarcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 780461.	1.8	28
26	Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nature Communications, 2020, 11, 4878.	5.8	27
27	Tracheobronchial Adenoid Cystic Carcinoma: 50-Year Experience at the National Cancer Center, China. Annals of Thoracic Surgery, 2019, 108, 873-882.	0.7	26
28	Analysis of a registry database for esophageal cancer from high-volume centers in China. Ecological Management and Restoration, 2020, 33, .	0.2	25
29	PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3055-3065.	1.2	24
30	Low frequency of TERT promoter somatic mutation in 313 sporadic esophageal squamous cell carcinomas. International Journal of Cancer, 2014, 134, 493-494.	2.3	23
31	Xerophilusin B Induces Cell Cycle Arrest and Apoptosis in Esophageal Squamous Cell Carcinoma Cells and Does Not Cause Toxicity in Nude Mice. Journal of Natural Products, 2015, 78, 10-16.	1.5	23
32	Associations of PGK1 promoter hypomethylation and PGK1â€mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA panâ€cancer analysis. Cancer Communications, 2019, 39, 1-17.	3.7	23
33	Prognostic value of tumor-infiltrating lymphocytes in esophageal cancer: an updated meta-analysis of 30 studies with 5,122 patients. Annals of Translational Medicine, 2020, 8, 822-822.	0.7	23
34	Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics. Journal of Cancer Research and Clinical Oncology, 2020, 146, 821-841.	1.2	22
35	Prognostic Impact of Metabolism Reprogramming Markers Acetyl-CoA Synthetase 2 Phosphorylation and Ketohexokinase-A Expression in Non-Small-Cell Lung Carcinoma. Frontiers in Oncology, 2019, 9, 1123.	1.3	21
36	Knockdown of <i>KLF5</i> promotes cisplatinâ€induced cell apoptosis via regulating DNA damage checkpoint proteins in nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 1069-1077.	0.8	18

#	Article	IF	Citations
37	PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. Human Pathology, 2019, 84, 291-298.	1.1	18
38	Development and validation of clinical diagnostic models for the probability of malignancy in solitary pulmonary nodules. Thoracic Cancer, 2014, 5, 162-168.	0.8	16
39	Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review. Targeted Oncology, 2021, 16, 425-434.	1.7	16
40	Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes. Nature Communications, 2021, 12, 3785.	5.8	16
41	Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma. Cancer Science, 2022, 113, 648-659.	1.7	16
42	Sintilimab for the treatment of non-small cell lung cancer. Biomarker Research, 2022, 10, 23.	2.8	16
43	The high expression instead of mutation of p53 is predictive of overall survival in patients with esophageal squamousâ€eell carcinoma: a metaâ€analysis. Cancer Medicine, 2017, 6, 54-66.	1.3	15
44	Elevated SLC2A1 Expression Correlates with Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics. DNA and Cell Biology, 2020, 39, 631-644.	0.9	15
45	Prognostic Impact of PCK1 Protein Kinase Activity-Dependent Nuclear SREBP1 Activation in Non-Small-Cell Lung Carcinoma. Frontiers in Oncology, 2021, 11, 561247.	1.3	13
46	Comprehensive Analysis of Ferroptosis Regulators in Lung Adenocarcinomas Identifies Prognostic and Immunotherapy-Related Biomarkers. Frontiers in Molecular Biosciences, 2021, 8, 587436.	1.6	13
47	Monoacylglycerol Lipase Knockdown Inhibits Cell Proliferation and Metastasis in Lung Adenocarcinoma. Frontiers in Oncology, 2020, 10, 559568.	1.3	12
48	Construction and Comprehensive Analyses of a METTL5-Associated Prognostic Signature With Immune Implication in Lung Adenocarcinomas. Frontiers in Genetics, 2020, 11, 617174.	1.1	12
49	Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study. World Journal of Surgical Oncology, 2017, 15, 197.	0.8	11
50	Association of phosphoenolpyruvate carboxykinase 1 protein kinase activity-dependent sterol regulatory element-binding protein 1 activation with prognosis of oesophageal carcinoma. European Journal of Cancer, 2021, 142, 123-131.	1.3	11
51	Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of nonâ€smallâ€cell lung cancer: A multicenter in vitro diagnostic clinical trial. Cancer Science, 2020, 111, 1739-1749.	1.7	11
52	Identification and validation of cellular senescence patterns to predict clinical outcomes and immunotherapeutic responses in lung adenocarcinoma. Cancer Cell International, 2021, 21, 652.	1.8	11
53	Efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC) Journal of Clinical Oncology, 2019, 37, 8531-8531.	0.8	10
54	Profiling of 520 Candidate Genes in 50 Surgically Treated Chinese Small Cell Lung Cancer Patients. Frontiers in Oncology, 2021, 11, 644434.	1.3	7

#	Article	IF	CITATIONS
55	Phosphorylation of Mutationally Introduced Tyrosine in the Activation Loop of HER2 Confers Gain-of-Function Activity. PLoS ONE, 2015, 10, e0123623.	1.1	6
56	Loss of SUSD2 expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma. Journal of Cancer, 2020, 11, 1648-1656.	1.2	6
57	Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art. Journal of Oncology, 2022, 2022, 1-11.	0.6	6
58	Cross-talk of pyroptosis and tumor immune landscape in lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 4423-4444.	1.3	6
59	The Deubiquitinase USP13 Maintains Cancer Cell Stemness by Promoting FASN Stability in Small Cell Lung Cancer. Frontiers in Oncology, 0, 12, .	1.3	5
60	Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases. Lung Cancer, 2021, 157, 116-123.	0.9	4
61	Application of SAW gas chromatography in the early screening of lung cancer. , 2015, , .		3
62	Development and validation of m6A RNA methylation regulators-based signature in lung adenocarcinoma. Chinese Medical Journal, 2021, 134, 2128-2130.	0.9	3
63	Prognostic immunohistochemical markers for small cell lung cancer: A review. Pathology Research and Practice, 2021, 217, 153311.	1.0	2
64	Abstract LB-397: Deep sequencing of Xenografts and case-matched blood and primary tumors reveals a 20 folds enrichment of loss of heterozygosity versus somatic mutations suggesting LOH plays an ever important role in tumorigenesis. , 2012, , .		2
65	Ferroptosis Characterization in Lung Adenocarcinomas Reveals Prognostic Signature With Immunotherapeutic Implication. Frontiers in Cell and Developmental Biology, 2021, 9, 743724.	1.8	2
66	Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for stage I lung adenocarcinoma. Translational Lung Cancer Research, 2021, 11, 0-0.	1.3	2
67	A Complement-Related Gene Signature for Predicting Overall Survival and Immunotherapy Efficacy in Sarcoma Patients. Frontiers in Cell and Developmental Biology, 2022, 10, 765062.	1.8	2
68	MiRACLe: an individual-specific approach to improve microRNA-target prediction based on a random contact model. Briefings in Bioinformatics, 2021, 22, .	3.2	1
69	Abstract 2351: Identification of somatic mutations in esophageal squamous cell carcinoma and corresponding xenograft by next-generation sequencing. , 2012 , , .		1
70	Choline Kinase Alpha2 Promotes Lipid Droplet Lipolysis in Non-Small-Cell Lung Carcinoma. Frontiers in Oncology, 2022, 12, 848483.	1.3	1
71	Abstract 4759: Identification of ALK, ROS1, FGFR2 and NRG1 fusions and validation with targeted inhibitors in lung and ovarian PDX models. , 2016 , , .		0
72	PGK1 Promoter Hypomethylation and PGK1-Mediated PDHK1 Phosphorylation Associate with Stage and Prognosis in Multiple Human Cancers. SSRN Electronic Journal, 0, , .	0.4	0